Hypertension Caused by Lenvatinib and Everolimus in the Treatment of Metastatic Renal Cell Carcinoma

Multikinase inhibitors (MKI) and mammalian target of rapamycin (mTOR) inhibitors prolong progression-free (PFS) and overall survival (OS) in the treatment of metastatic renal cell carcinoma (mRCC) by reducing angiogenesis and tumor growth. In this regard, the MKI lenvatinib and the mTOR inhibitor ev...

Descripción completa

Detalles Bibliográficos
Autores principales: Bendtsen, Mathias Alrø Fichtner, Grimm, Daniela, Bauer, Johann, Wehland, Markus, Wise, Petra, Magnusson, Nils E., Infanger, Manfred, Krüger, Marcus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5578126/
https://www.ncbi.nlm.nih.gov/pubmed/28796163
http://dx.doi.org/10.3390/ijms18081736

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5578126/
https://www.ncbi.nlm.nih.gov/pubmed/28796163
http://dx.doi.org/10.3390/ijms18081736

Ejemplares similares